A Randomized Study to Evaluate the Effect of Switching From Efavirenz to Atazanavir/ Ritonavir on Lipoatrophy and Mitochondrial Dysfunction in HIV-infected Subjects With Good Virologic Suppression.
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Atazanavir/ritonavir (Primary) ; Efavirenz
- Indications HIV infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Feb 2012 Actual patient number 1 added as reported by ClinicalTrials.gov.